Advertisement

Supportive Care in Cancer

, Volume 21, Issue 4, pp 1193–1199 | Cite as

Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA

  • Pamela J. Atherton
  • Michele Y. Halyard
  • Jeff A. Sloan
  • Robert C. Miller
  • Richard L. Deming
  • T. H. Patricia Tai
  • Kathy J. Stien
  • James A. MartensonJr.Email author
Original Article

Abstract

Purpose

The Bowel Function Questionnaire (BFQ) has been used in clinical trials to assess symptoms during and after pelvic radiotherapy (RT). This study evaluated the importance of symptoms in the BFQ from a patient perspective.

Methods

Patients reported presence or absence of symptoms and rated importance of symptoms at baseline, 4 weeks after completion of pelvic RT, and 12 and 24 months after RT. The BFQ measured overall quality of life (QOL) and symptoms of nocturnal bowel movements, incontinence, clustering, need for protective clothing, inability to differentiate stool from gas, liquid bowel movements, urgency, cramping, and bleeding. Bowel movement frequency also was recorded. A content validity questionnaire (CVQ) was used to rate symptoms as “not very important,” “moderately unimportant,” “neutral,” “moderately important,” or “very important.”

Results

Most of the 125 participating patients rated all symptoms as moderately or very important. Generally, patients gave similar ratings for symptom importance at all study points, and ratings were independent of whether the patient experienced the symptom. Measures of greatest importance (moderately or very important) at baseline were ability to control bowel movements (94 %), not having to wear protective clothing (90 %), and not having rectal bleeding (94 %). With the exception of need for protective clothing, the presence of a symptom at 4 weeks was associated with significantly worse QOL (P < .01 for all).

Conclusions

The BFQ has excellent content validity. Patients rated most symptoms as moderately or very important, indicating the BFQ is an appropriate tool for symptom assessment during and after pelvic RT.

Keywords

Bowel function Content validity Pelvic radiotherapy Quality of life 

Abbreviations

BFQ

Bowel function questionnaire

CVQ

Content validity questionnaire

NCCTG

North Central Cancer Treatment Group

PR

Pelvic radiotherapy

QOL

Quality of life

Notes

Acknowledgments

This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported, in part, by Public Health Service grants CA-25224, CA-60276, CA-35101, CA-35103, CA-35415, CA-35431, CA-63849, CA-35269, CA-35119, CA-37417, CA-35267, CA-52654, and CA-35195.

Additional institutions that enrolled patients in this study included: Duluth CCOP, Duluth, MN, USA (Daniel A. Nikcevich, MD); Mayo Clinic, Jacksonville, FL, USA (Kurt A. Jaeckle, MD); Sioux Community Cancer Consortium, Sioux Falls, SD, USA (Miroslaw Mazurczak, MD); Spartanburg Regional Medical Center, Spartanburg, SC, USA (James D. Bearden, III, MD); Meritcare Hospital CCOP, Fargo, ND, USA (Preston D. Steen, MD); Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN, USA (Patrick J. Flynn, MD); Carle Cancer Center CCOP, Urbana, IL, USA (Kendrith M. Rowland, Jr, MD); Montana Cancer Consortium, Billings, MT, USA (Benjamin T. Marchello, MD); and Wichita Community Clinical Oncology Program, Wichita, KS, USA (Shaker R. Dakhil, MD).

Conflict of interest

None.

References

  1. 1.
    Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL et al (2003) North Central Cancer Treatment Group. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 21(9):1669–1674PubMedCrossRefGoogle Scholar
  2. 2.
    Martenson JA Jr, Hyland G, Moertel CG, Mailliard JA, O’Fallon JR, Collins RT et al (1996) Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys 35(2):299–303PubMedCrossRefGoogle Scholar
  3. 3.
    Martenson JA, Bollinger JW, Sloan JA, Novotny PJ, Urias RE, Michalak JC et al (2000) Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: a North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. J Clin Oncol 18(6):1239–1245PubMedGoogle Scholar
  4. 4.
    Martenson JA, Halyard MY, Sloan JA, Proulx GM, Miller RC, Deming RL et al (2008) Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA. J Clin Oncol 26(32):5248–5253, Epub 2008 Sep 2PubMedCrossRefGoogle Scholar
  5. 5.
    Miller RC, Martenson JA, Sargent DJ, Kahn MJ, Krook JE (1998) Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys 41(3):593–598PubMedCrossRefGoogle Scholar
  6. 6.
    Miller RC, Sargent DJ, Martenson JA, Macdonald JS, Haller D, Mayer RJ et al (2002) Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. Int J Radiat Oncol Biol Phys 54(2):409–413PubMedCrossRefGoogle Scholar
  7. 7.
    Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM (1994) The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 220(5):676–682PubMedCrossRefGoogle Scholar
  8. 8.
    Glickman S, Kamm MA (1996) Bowel dysfunction in spinal-cord-injury patients. Lancet 347(9016):1651–1653PubMedCrossRefGoogle Scholar
  9. 9.
    Chia YW, Lee TK, Kour NW, Tung KH, Tan ES (1996) Microchip implants on the anterior sacral roots in patients with spinal trauma: does it improve bowel function? Dis Colon Rectum 39(6):690–694PubMedCrossRefGoogle Scholar
  10. 10.
    Crook J, Esche B, Futter N (1996) Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient’s perspective. Urology 47(3):387–394PubMedCrossRefGoogle Scholar
  11. 11.
    Crowell MD, Dubin NH, Robinson JC, Cheskin LJ, Schuster MM, Heller BR et al (1994) Functional bowel disorders in women with dysmenorrhea. Am J Gastroenterol 89(11):1973–1977PubMedGoogle Scholar
  12. 12.
    Garcia Compean D, Ramos Jimenez J, Guzman de la Garza F, Saenz C, Maldonado H, Barragan RF et al (1994) Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. AIDS 8(11):1563–1567Google Scholar
  13. 13.
    Gebbia V, Carreca I, Testa A, Valenza R, Curto G, Cannata G et al (1993) Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 4(4):443–445PubMedCrossRefGoogle Scholar
  14. 14.
    McMillan SC, Williams FA (1989) Validity and reliability of the Constipation Assessment Scale. Cancer Nurs 12(3):183–188PubMedCrossRefGoogle Scholar
  15. 15.
    Graf W, Ekstrom K, Glimelius B, Pahlman L (1996) A pilot study of factors influencing bowel function after colorectal anastomosis. Dis Colon Rectum 39(7):744–749PubMedCrossRefGoogle Scholar
  16. 16.
    Haddock MG, Sloan JA, Bollinger JW, Soori G, Steen PD, Martenson JA (2007) North Central Cancer Treatment Group. Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial. J Clin Oncol 25(10):1255–1259PubMedCrossRefGoogle Scholar
  17. 17.
    Ho YH, Low D, Goh HS (1996) Bowel function survey after segmental colorectal resections. Dis Colon Rectum 39(3):307–310PubMedCrossRefGoogle Scholar
  18. 18.
    Kannisto M, Rintala R (1995) Bowel function in adults who have sustained spinal cord injury in childhood. Paraplegia 33(12):701–703PubMedCrossRefGoogle Scholar
  19. 19.
    Kapadia SA, Raimundo AH, Grimble GK, Aimer P, Silk DB (1995) Influence of three different fiber-supplemented enteral diets on bowel function and short-chain fatty acid production. JPEN J Parenter Enteral Nutr 19(1):63–68PubMedCrossRefGoogle Scholar
  20. 20.
    Rintala RJ, Lindahl H (1995) Is normal bowel function possible after repair of intermediate and high anorectal malformations? J Pediatr Surg 30(3):491–494PubMedCrossRefGoogle Scholar
  21. 21.
    Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O’Fallon JR, Mahoney MR et al (1998) Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 16(11):3662–3673PubMedGoogle Scholar
  22. 22.
    Sloan JA, Dueck AC, Erickson PA, Guess H, Revicki DA, Santanello NC (2007) Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Analysis and interpretation of results based on patient-reported outcomes. Value Health 10(Suppl 2):S106–S115PubMedCrossRefGoogle Scholar
  23. 23.
    Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G et al (2007) National Cancer Institute. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 25(32):5070–5077PubMedCrossRefGoogle Scholar
  24. 24.
    Dahlberg M, Glimelius B, Graf W, Pahlman L (1998) Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 41(5):543–549PubMedCrossRefGoogle Scholar
  25. 25.
    Lange MM, den Dulk M, Bossema ER, Maas CP, Peeters KC, Rutten HJ et al (2007) Cooperative clinical investigators of the Dutch Total Mesorectal Excision Trial. Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg 94(10):1278–1284PubMedCrossRefGoogle Scholar
  26. 26.
    Lundby L, Krogh K, Jensen VJ, Gandrup P, Qvist N, Overgaard J et al (2005) Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum 48(7):1343–1349PubMedCrossRefGoogle Scholar
  27. 27.
    Nout RA, van de Poll-Franse LV, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW et al (2011) Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 29(13):1692–1700, Epub 2011 Mar 28PubMedCrossRefGoogle Scholar
  28. 28.
    Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol 23(25):6199–6206PubMedCrossRefGoogle Scholar
  29. 29.
    Pinkawa M, Piroth MD, Holy R, Fischedick K, Klotz J, Szekely-Orban D et al (2011) Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison. Int J Radiat Oncol Biol Phys 81(1):23–28, Epub 2010 Sep 9PubMedCrossRefGoogle Scholar
  30. 30.
    Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G et al (2010) Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76(4):1005–1011, Epub 2009 Jun 18PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Pamela J. Atherton
    • 1
  • Michele Y. Halyard
    • 4
  • Jeff A. Sloan
    • 1
  • Robert C. Miller
    • 2
  • Richard L. Deming
    • 5
  • T. H. Patricia Tai
    • 6
  • Kathy J. Stien
    • 3
  • James A. MartensonJr.
    • 2
    Email author
  1. 1.Division of Biomedical Statistics and InformaticsMayo ClinicRochesterUSA
  2. 2.Department of Radiation OncologyMayo ClinicRochesterUSA
  3. 3.Department of Neurologic SurgeryMayo ClinicRochesterUSA
  4. 4.Department of Radiation OncologyMayo ClinicScottsdaleUSA
  5. 5.Department of Radiation OncologyIowa Oncology Research Association CCOPDes MoinesUSA
  6. 6.Allan Blair Cancer CentreReginaCanada

Personalised recommendations